Red Star Capital Bureau reported on January 9 that today, the official WeChat official account of "MSD China" announced that the two dose vaccination procedure (June December) for women aged 9-14 years old with the ninvalent human papillomavirus vaccine (Saccharomyces cerevisiae) (trade name: Jiadaxiu 9, namely, the ninvalent HPV vaccine) had been approved by the State Food and Drug Administration.
This approval means that Jiada Xiu 9 will add a second dose vaccination program for 9-14 years old. Prior to this, the Merck Tohmatsu nine valent HPV vaccine used a three dose immunization program, priced at 1318 yuan per dose in public medical institutions, with a total cost of 3954 yuan per dose.
In August 2023, MSD China announced the age expansion of its nine valent HPV vaccine. The target audience has expanded from 16-26 years old to women of appropriate age between 9-45 years old.
In addition, the Merck East Nine valent HPV vaccine remains the only approved and marketed nine valent HPV vaccine in China. Zhifei Biotechnology (300122. SZ) is the exclusive agent and announced at the end of January 2023 that the renewal of the exclusive agency for Merck East HPV vaccine has been successful. The procurement amount has significantly increased from 28.106 billion yuan in the previous agreement period to 97.957 billion yuan.
In terms of domestic manufacturers, Wantai Biotechnology (603392. SH) launched its bivalent HPV vaccine (trade name: Xinkening Cecolin) in May 2020, which was the first domestically produced cervical cancer vaccine to be approved for sale; In May of this year, the first batch of bivalent HPV vaccines produced by Yuxi Zerun, a subsidiary of Watson Biotech (300142. SZ), obtained the "Biological Product Batch Issuance Certificate", marking the arrival of the second bivalent HPV vaccine in China.
According to the official website of the Shanghai Stock Exchange e-interactive platform, on December 14, 2023, Wantai Biotechnology responded to investor inquiries by stating that the on-site work for the V8 phase visit of the company's nine-valent HPV vaccine phase III main clinical trial has been completed and specimen testing is currently underway. Meanwhile, this vaccine can be used as an iterative vaccine for market application.
However, regarding the launch time of its nine valent HPV vaccine, Wantai Biotechnology stated that there are many types of specimen testing and the testing process is complex. After the testing is completed, quality control of the data is also required. The specific time will depend on the progress of each link, and it has developed corresponding promotion plans, which are currently being executed according to the plan.
Red Star News reporter Deng Lingyao